Monocaprin eye drop formulation to combat antibiotic resistant gonococcal blindness

Abstract Neisseria gonorrhoeae bacteria are acknowledged as an urgent threat to human health because this species has developed resistances to all of the antibiotics used clinically to treat its infections. N. gonorrhoeae causes the sexually transmitted disease gonorrhoea, but also causes blindness...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Colin P. Churchward, Ali A. Al-Kinani, Hamdy Abdelkader, Julian Swinden, Opeoluwa Siwoku, Thinuba Varnakulasingam, Raid G. Alany, Lori A. S. Snyder
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ab1f3f4beb1d41dbb7baaf6f77fe8e42
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ab1f3f4beb1d41dbb7baaf6f77fe8e42
record_format	dspace
spelling	oai:doaj.org-article:ab1f3f4beb1d41dbb7baaf6f77fe8e422021-12-02T16:26:21ZMonocaprin eye drop formulation to combat antibiotic resistant gonococcal blindness10.1038/s41598-020-68722-82045-2322https://doaj.org/article/ab1f3f4beb1d41dbb7baaf6f77fe8e422020-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-68722-8https://doaj.org/toc/2045-2322Abstract Neisseria gonorrhoeae bacteria are acknowledged as an urgent threat to human health because this species has developed resistances to all of the antibiotics used clinically to treat its infections. N. gonorrhoeae causes the sexually transmitted disease gonorrhoea, but also causes blindness when the bacteria infect the eyes. Infants are particularly susceptible, acquiring the infection from their mothers at birth. We have shown that the monoglyceride monocaprin rapidly kills N. gonorrhoeae and other bacterial species and is non-irritating in ocular assays. Here we show that the physical and chemical properties of monocaprin make it ideal for use in a thickened eye drop formulation to combat eye infections. Monocaprin-containing formulations were assessed using analytical techniques and for antimicrobial activity in vitro and in ex vivo infections. Monocaprin-containing formulations retained activity after three years and are non-irritating, unlike preparations of povidone iodine in our assays. A recommended formulation for further development and investigation is 0.25% monocaprin in 1% HPMC with 1% polysorbate 20.Colin P. ChurchwardAli A. Al-KinaniHamdy AbdelkaderJulian SwindenOpeoluwa SiwokuThinuba VarnakulasingamRaid G. AlanyLori A. S. SnyderNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-10 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Colin P. Churchward Ali A. Al-Kinani Hamdy Abdelkader Julian Swinden Opeoluwa Siwoku Thinuba Varnakulasingam Raid G. Alany Lori A. S. Snyder Monocaprin eye drop formulation to combat antibiotic resistant gonococcal blindness
description	Abstract Neisseria gonorrhoeae bacteria are acknowledged as an urgent threat to human health because this species has developed resistances to all of the antibiotics used clinically to treat its infections. N. gonorrhoeae causes the sexually transmitted disease gonorrhoea, but also causes blindness when the bacteria infect the eyes. Infants are particularly susceptible, acquiring the infection from their mothers at birth. We have shown that the monoglyceride monocaprin rapidly kills N. gonorrhoeae and other bacterial species and is non-irritating in ocular assays. Here we show that the physical and chemical properties of monocaprin make it ideal for use in a thickened eye drop formulation to combat eye infections. Monocaprin-containing formulations were assessed using analytical techniques and for antimicrobial activity in vitro and in ex vivo infections. Monocaprin-containing formulations retained activity after three years and are non-irritating, unlike preparations of povidone iodine in our assays. A recommended formulation for further development and investigation is 0.25% monocaprin in 1% HPMC with 1% polysorbate 20.
format	article
author	Colin P. Churchward Ali A. Al-Kinani Hamdy Abdelkader Julian Swinden Opeoluwa Siwoku Thinuba Varnakulasingam Raid G. Alany Lori A. S. Snyder
author_facet	Colin P. Churchward Ali A. Al-Kinani Hamdy Abdelkader Julian Swinden Opeoluwa Siwoku Thinuba Varnakulasingam Raid G. Alany Lori A. S. Snyder
author_sort	Colin P. Churchward
title	Monocaprin eye drop formulation to combat antibiotic resistant gonococcal blindness
title_short	Monocaprin eye drop formulation to combat antibiotic resistant gonococcal blindness
title_full	Monocaprin eye drop formulation to combat antibiotic resistant gonococcal blindness
title_fullStr	Monocaprin eye drop formulation to combat antibiotic resistant gonococcal blindness
title_full_unstemmed	Monocaprin eye drop formulation to combat antibiotic resistant gonococcal blindness
title_sort	monocaprin eye drop formulation to combat antibiotic resistant gonococcal blindness
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/ab1f3f4beb1d41dbb7baaf6f77fe8e42
work_keys_str_mv	AT colinpchurchward monocaprineyedropformulationtocombatantibioticresistantgonococcalblindness AT aliaalkinani monocaprineyedropformulationtocombatantibioticresistantgonococcalblindness AT hamdyabdelkader monocaprineyedropformulationtocombatantibioticresistantgonococcalblindness AT julianswinden monocaprineyedropformulationtocombatantibioticresistantgonococcalblindness AT opeoluwasiwoku monocaprineyedropformulationtocombatantibioticresistantgonococcalblindness AT thinubavarnakulasingam monocaprineyedropformulationtocombatantibioticresistantgonococcalblindness AT raidgalany monocaprineyedropformulationtocombatantibioticresistantgonococcalblindness AT loriassnyder monocaprineyedropformulationtocombatantibioticresistantgonococcalblindness
_version_	1718384073875914752

Monocaprin eye drop formulation to combat antibiotic resistant gonococcal blindness

Ejemplares similares